- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01813929
Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes (MeT1)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Denver
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 20-59 years of age,
- Type 1 diabetes based on antibody-positivity, rapid persistent conversion to insulin requirement after diagnosis, absent C-peptide, or DKA at diagnosis, or a clinical course consistent with T1D,
- HbA1c 6.0 - 9.5, and
- Willing and able to commit to two 6 week-long periods of blinded medication followed by hyperinsulinemic euglycemic clamp, vascular testing, and muscle biopsies.
Exclusion Criteria:
Any comorbid condition associated with:
- inflammation,
- insulin Resistance, or
dyslipidemia including:
- cancer,
- heart failure,
- active or end stage liver disease,
- kidney disease, or
- rheumatological disease;
- Tobacco use;
- Pregnancy or women who are breastfeeding;
- Steroid use;
- Scheduled strenuous physical activity >3 days a week;
- Angina, known CAD, or any other cardiovascular or pulmonary disease;
- A history of COPD or asthma;
- Presence of systolic blood pressure >190 at rest or >250 with exercise, or diastolic pressure >95 at rest or >105 with exercise;
- Untreated thyroid disease;
- Proteinuria (urine protein >200 mg/dl) or a creatinine > 1.5 mg/dl (males) or 1.4 mg/dL (females), suggestive of severe renal disease;
- Severe Proliferative retinopathy;
- Niacin treatment;
- Administration of experimental agent for T1D within 30 days prior to screening;
- Recent (prior 6 months) or current metformin or thiazolidenedione use;
- Hypoglycemia unawareness or recurrent severe hypoglycemia (no symptoms of hypoglycemia with FSBS<40 and episodes of this severity >1 per week);
- Weight instability (weight change >5% in last 6 months);
- History of any organ transplant, including islet cell transplant;
- Current or prior infection with HIV, hepatitis B or hepatitis C or hepatic -insufficiency (AST or ALT > 2x the upper limits of normal);
- Any condition, medical or otherwise that would, in the opinion of the investigator, prevent complete participation in the study, or that would pose a significant hazard to the subject;
- History of substance abuse within the 12 months prior to screening.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador de placebos: Placebo
|
Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
|
Experimental: Metformina
|
Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention.
If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Insulin Sensitivity by Hyperinsulinemic Euglycemic Clamp
Periodo de tiempo: End of each 6 week intervention period
|
Determine the effect of metformin on insulin sensitivity in T1D.
Reported measure is glucose infusion rate during hyperinsulinemic euglycemic clamp normalized to total body weight.
For this measure, insulin was infused at 40 mU/m2 surface area.
Blood sugar wass checked every 5 minutes and glucose infusion adjusted to maintain glucose level at 90 mg/dL for 2 hours.
The glucose infusion rate for the final 30 minutes is reported as GIR (aka M-value or glucose disposal rate) in mg glucose/kg*min.
A higher value corresponds to greater sensitivity to insulin.
There is no strictly defined normal range.
|
End of each 6 week intervention period
|
Flow-mediated Brachial Artery Dilation
Periodo de tiempo: End of each 6 week intervention period
|
Measure of endothelial function by brachial ultrasound of the percent dilation after 5 minutes of occlusion.
|
End of each 6 week intervention period
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Arterial Stiffness by PWV
Periodo de tiempo: End of each 6 week intervention period
|
Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec.
|
End of each 6 week intervention period
|
Arterial Stiffness by AI@75
Periodo de tiempo: End of each 6 week intervention period
|
Augmentation index by Sphygmacor is a measure of aortic arterial stiffness.
AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.
|
End of each 6 week intervention period
|
Mitochondrial Measures: Oxygen Consumption
Periodo de tiempo: End of each 6 week intervention period
|
Oxygen consumption rate with various substrates and max uncoupled O2 consumption. Measure is performed on permeabilized muscle fibers from biopsy tissue from the vastus lateralis using the Oroboros OxygraphO2k high resolution respirometer. State 3 is full coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. state 4 is after addition of oligomycin to inhibit the ATP synthase and thus corresponds to the maximum leak state where O2 consumption is limited by the buildup of the proton gradient and can only proceed as fast as the protons can leak back across the membrane. FCCP is added as an uncoupler, allowing free leakage of protons across the inner membrane, and thus measures maximum possible O2 flux. There are no defined normal ranges, but higher state 3 and uncoupled flux indicate better mitochondrial function, while state 4 is needed to correct state 3 to the fully coupled flux. |
End of each 6 week intervention period
|
Mitochondrial Measures: Protein Expression Levels of Electron Transport Chain Complexes
Periodo de tiempo: End of each 6 week intervention period
|
Mito content by Western Blotting of electron transport chain complexes I, II, III, and V. complex 1 utilizes NADH from pyruvate/malate/glutamate while complex II utilizes FADH from succinate.
complex III is the cytochrome c reductase while complex V is the ATP synthase.
|
End of each 6 week intervention period
|
Inflammatory Marker: hsCRP
Periodo de tiempo: End of each 6 week intervention period
|
hsCRP (mg/L) by Beckman Coulter assay
|
End of each 6 week intervention period
|
Heart Rate Variability
Periodo de tiempo: End of each 6 week intervention period
|
measure of autonomic function: ratio of fastest to slowest heart rate during valsalva maneuver
|
End of each 6 week intervention period
|
Continuous Glucose Monitor Measures of Mean Glucose
Periodo de tiempo: Last Week of each 6 Week Intervention Period (over 7 days)
|
Mean Glucose & Glucose Standard Deviation (Glycemic Variability) by Dexcom CGM
|
Last Week of each 6 Week Intervention Period (over 7 days)
|
Continuous Glucose Monitor Measures of Hypoglycemia
Periodo de tiempo: Last Week of each 6 Week Intervention Period (over 7 days)
|
Percent of time less than 70 mg/dL during the final week of each phase by Dexcom CGM.
|
Last Week of each 6 Week Intervention Period (over 7 days)
|
Metabolic Markers: Glucagon
Periodo de tiempo: End of each 6 week intervention period
|
Glucagon (pg/ml); baseline on AM of each phase final study visit.
|
End of each 6 week intervention period
|
Metabolic Markers: Glucose, Triglycerides, Cholesterol
Periodo de tiempo: End of each 6 week intervention period
|
Glucose (mg/dL), triglycerides (mg/dL), cholesterol (mg/dL) at baseline after each phase
|
End of each 6 week intervention period
|
Metabolic Markers: Fatty Acids
Periodo de tiempo: End of each 6 week intervention period
|
fatty acids (microeq/L) at baseline after each phase in the AM of the final visit
|
End of each 6 week intervention period
|
Metabolic Markers: Glycerol
Periodo de tiempo: End of each 6 week intervention period
|
glycerol (micromol/L) at baseline after each phase in the AM of the final phase visit
|
End of each 6 week intervention period
|
Metabolic Markers: Insulin
Periodo de tiempo: End of each 6 week intervention period
|
insulin (microIU/ml) at baseline after each phase in the AM of the final phase visit
|
End of each 6 week intervention period
|
Metabolic Markers: Lactate
Periodo de tiempo: End of each 6 week intervention period
|
lactate (mmol/L) at baseline after each phase in the AM of the final phase visit
|
End of each 6 week intervention period
|
Metabolic Markers: Adiponection
Periodo de tiempo: End of each 6 week intervention period
|
adiponection (microg/ml) at baseline after each phase in the AM of the final phase visit
|
End of each 6 week intervention period
|
Vascular Markers: Endothelin-1 (pg/ml)
Periodo de tiempo: End of each 6 week intervention period
|
endothelin-1 at baseline after each phase in the AM of the final phase visit by peninsula labs radioimmunoassay
|
End of each 6 week intervention period
|
In Vivo Mitochondrial Function: Ratio of the Amount of ATP Generated Per Unit of Oxygen Consumed
Periodo de tiempo: End of each 6 week intervention period
|
Measured by 31P-mass spec.
This ratio measures mitochondrial efficiency.
The higher the ratio, the more efficiently the individual converts metabolic substrates into ATP, with the ATP then available for energy-demanding cellular processes such as protein synthesis and biomass production
|
End of each 6 week intervention period
|
In Vivo Mitochondrial Function: Time Constants
Periodo de tiempo: End of each 6 week intervention period
|
Measured by 31P-mass spec.
ADP time constant and phosphocreatine time constant.
ADP time constant is a measure of the time required to convert ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism).
A faster recovery is a better outcome; a slower recovery is a worse outcome.
Similarly for phosphocreatine.
|
End of each 6 week intervention period
|
In Vivo Mitochondrial Function: QMax, VPCr
Periodo de tiempo: End of each 6 week intervention period
|
Measured by 31P-mass spec. For each measure, a higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted.
|
End of each 6 week intervention period
|
In Vivo Mitochondrial Function: Oxidative Phosphorylation
Periodo de tiempo: End of each 6 week intervention period
|
Measured by 31P-mass spec.
A higher value indicates better mitochondrial function.
All re calculated from multiple measures from the MRS spectra.
These are relatively new research measures and normal values are not known or generally accepted.
Oxidative Phosphorylation measures the rate at which electron transport activity generates phosphorylated energy sources (ATP and PCr)
|
End of each 6 week intervention period
|
In Vivo Mitochondrial Function:AnGly
Periodo de tiempo: End of each 6 week intervention period
|
Measured by 31P-mass spec.
Anaerobic glycolysis measures the amount of anaerobic ATP generation for energy.
It is generally felt that a higher value here reflects impaired mitochondrial function necessitating greater reliance on anaerobic metabolism.
|
End of each 6 week intervention period
|
Cardiac Function
Periodo de tiempo: End of each 6 week intervention period
|
Cardiac output
|
End of each 6 week intervention period
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Vascular Markers: PAI-1
Periodo de tiempo: End of each 6 week intervention period
|
PAI-1 exploratory thromobotic marker.
|
End of each 6 week intervention period
|
Vascular Markers: Exploratory
Periodo de tiempo: End of each 6 week intervention period
|
ICAM
|
End of each 6 week intervention period
|
Oxidative Stress Markers
Periodo de tiempo: End of each 6 week intervention period
|
TBARs, GSSG:GSH ratio
|
End of each 6 week intervention period
|
Mitochondrial Measures: Oxidant Generation
Periodo de tiempo: End of each 6 week intervention period
|
oxidant generation
|
End of each 6 week intervention period
|
Inflammatory Markers: Exploratory
Periodo de tiempo: End of each 6 week intervention period
|
IL6, TNF alpha
|
End of each 6 week intervention period
|
Mitochondrial Oxidant Generation
Periodo de tiempo: after each 6 week intervention
|
exploratory measure looking at H2O2 production.
not performed due to equipment not available.
|
after each 6 week intervention
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Irene Schauer, MD, PhD, University of Colorado, Denver
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 11-0693
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes tipo 1
-
Oxford Brookes UniversityUniversity of OxfordTerminadoActividad física | Salud Mental Bienestar 1 | Función Cognitiva 1, Social | Academic Attainment | Fitness TestingReino Unido
-
Merck Sharp & Dohme LLCReclutamientoCáncer de pulmón de células no pequeñas | Tumores sólidos | Muerte celular programada-1 (PD1, PD-1) | Ligando 1 de muerte celular programada 1 (PDL1, PD-L1) | Ligando 2 de muerte celular programada 1 (PDL2, PD-L2)Japón
-
Rambam Health Care CampusIsrael Science FoundationTerminado
-
Alvotech Swiss AGTerminado
-
PfizerTerminado
-
SanionaTerminado
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionTerminado
-
Calliditas Therapeutics ABTerminado
-
JKT Biopharma Co., Ltd.Reclutamiento
-
Graviton Bioscience CorporationTerminado
Ensayos clínicos sobre Metformin
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Johnson & Johnson Pharmaceutical Research & Development...Terminado
-
Janssen Research & Development, LLCTerminado
-
Boehringer IngelheimEli Lilly and CompanyTerminado
-
LG Life SciencesTerminado
-
Ain Shams UniversityDesconocido
-
Actavis Inc.TerminadoUn estudio de biodisponibilidad relativa de metformin HCl 750 mg ER Tablets en condiciones sin ayunoSaludableEstados Unidos
-
Tan Tock Seng HospitalReclutamiento
-
Joint Stock Company "Farmak"Terminado